BOSTON, March 8, 2006 — Neuromed Pharmaceuticals, a biopharmaceutical company developing next-generation chronic pain drugs, announced the completion of a Series D financing of $25 million. This fourth round of financing brings Neuromed's cumulative venture capital financing to $74 million. The Series D financing was completed with significant participation from existing investors including MPM Capital, Neuro Discovery LP, GrowthWorks Capital, CMDF, BDC Venture Capital, Cogene Biotech Ventures and the Royal Bank of Canada, as well as with the participation of one new investor, James Richardson & Sons Limited.
Goodwin Procter attorneys Mitchell Bloom and James Kasinger represented MPM Capital, James Richardson & Sons Limited and certain other investors in this transaction.